Tilray Shares Drop 1.77% to $7.75 After 13.6% Monthly Slide
Tilray shares closed at $7.75, down 1.77% on Feb 20 after slipping 13.6% over the past month versus the medical sector’s 0.8% gain. Analysts expect Q1 EPS of -$0.14 (86% YoY improvement) on $205.9 million revenue (+10.9%), with full-year sales of $872 million (+6.2%) and EPS at -$0.56.
1. Recent Stock Performance
Tilray Brands closed its latest session at $7.75, down 1.77% from the prior day’s close. Over the past month, the stock has declined 13.58%, underperforming the medical sector’s 0.77% gain and trailing the S&P 500’s 1% loss.
2. Q1 Earnings and Revenue Forecasts
Analysts project Tilray will post first-quarter EPS of -$0.14, representing an 86% improvement from the year-ago quarter, on revenue of $205.93 million, up 10.85% year-over-year. These figures underscore expectations of narrowing losses and accelerating top-line growth.
3. Full-Year Outlook and Analyst Ratings
For the full fiscal year, consensus estimates call for EPS of -$0.56 per share and revenue of $871.99 million, up 6.17% from last year. The company holds a Zacks Rank of #3 (Hold) and its medical products industry sits in the bottom 40% of over 250 industries.